Cyclin Dependent Kinase (CDK) Inhibitors Market Trends, Future Outlook, COVID-19 Impact Analysis, Forecast 2022-2028

The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a considerable CAGR during the forecast period. CDKs are nutrient metabolic enzymes that regulate the cell cycle. CDK binds to cyclin, forming a complex that works together. In the human body, there are approximately 20 members of the CDK family. Further, an inhibitor is any compound or chemical that inhibits the function of CDKs. Cancer cells proliferate excessively, and (CDK) inhibitors are used as a treatment to regulate this mechanism.

A full report of Cyclin Dependent Kinase (CDK) Inhibitors Market is available at: https://www.omrglobal.com/industry-reports/cyclin-dependent-kinase-cdk-inhibitors-market

Some of the key factors driving the market growth of the CDK Inhibitors market include a rise in R&D spending and activities along with the increase in oncology research across the globe. The CDK inhibitor market is a highly opportunistic field for anticancer treatment due to the extensive use of CDK inhibitors in numerous clinical trials. For instance, in 2021, the University of Adelaide researchers discovered new evidence about the beneficial role of androgens in breast cancer treatment, which has immediate implications for women with estrogen receptor-driven metastatic disease.

Furthermore, in September 2021, Novartis Pharma AG Kisqali is the first CDK4/6 inhibitor to demonstrate a statistically significant life extension benefit in the front-line treatment of postmenopausal women with HR-positive, HER2-negative breast cancer. Kisqali has already won two clinical trials under its belt showing a survival benefit over traditional treatment. Now, the company released its third CDK inhibitor clinical trial, the first-of-its-kind victory in newly diagnosed patients that could give it a better shot at challenging Pfizer's market-leading Ibrance.

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/cyclin-dependent-kinase-cdk-inhibitors-market

Market Coverage

• The market number available for - 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Type
o By Administration
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including Beta Pharma, Inc., Eli Lilly & Co., FLX Bio, Inc., G1 Therapeutics Inc., Novartis Pharma AG, and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Cyclin Dependent Kinase (CDK) Inhibitors Market Report Segment

By Type

• Specific inhibitors
• Non-Specific or Broad Range Inhibitors
• Multiple target inhibitors

By Material

• Nasal
• Oral
• Intravenous
• Intramuscular

By Distribution Channel

• Breast cancer
• Lymphoma
• Multiple Myeloma
• Ovarian cancer
• Others (Cystic Fibrosis)

Cyclin Dependent Kinase (CDK) Inhibitors Market- Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Novartis Pharma AG
• Onconova Therapeutics, Inc.
• Pfizer Inc.
• Teijin Ltd.
• ViroStatics srl
• Xuanzhu Biopharmaceutical Co., Ltd.

Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.